EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic Modulation by Dimethyl Fumarate Alters Docetaxel Responses in Prostate Cancer Cells

Andrés Coneo-Pretelt iD, Ana Peñata-Taborda iD, Lyda Espitia-Pérez iD, Luisa Jiménez-Vidal, Mario Negrette-Guzmán iD, Nathalia Jones-Cifuentes iD, Bladimiro Rincón-Orozco iD, Fabio Aristizábal-Gutiérrez, Pedro Espitia-Pérez iD

International Journal of Molecular Sciences · 11.07.2026 · 27 (14) · 6209

DOI: 10.3390/ijms27146209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.07.2026. Verfasst von Andrés Coneo-Pretelt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación Biomédica y Biología Molecular, Facultad de Ciencias de la Salud, Universidad del Sinú, Montería 230001, Colombia. Hauptthemen laut MEDLINE: Docetaxel, Dimethyl Fumarate, Prostatic Neoplasms, Antineoplastic Agents. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Tecnología e Innovación, Ministry of Science, Technology, and Innovation of Colombia, Universidad del Sinú.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dimethyl fumarate (DMF) is a clinically approved fumarate ester with pleiotropic effects and a promising candidate for drug repurposing in cancer. Here, we investigated whether low-dose DMF could modulate docetaxel (DCT) responses in prostate cancer cells. PC-3, LNCaP, and RWPE-1 cells were exposed to DMF and DCT individually or in combination, and cell viability, drug interaction profiles, apoptosis, oxidative stress, mitochondrial mass, glutathione status, glucose consumption, lactate production, LDHA/SOD2 expression, and oxygen consumption were evaluated. Low-dose DMF and DCT were well-tolerated in RWPE-1 normal prostate cells. In prostate cancer cells, the DMF–DCT combination was cytotoxic and strongly dose- and ratio-dependent, with the most favorable responses at higher exposures and under balanced or DCT-enriched regimens. DMF-DCT-treated LNCaP cells showed reduced viability, decreased lactate production, increased glucose consumption, mitochondrial dysfunction, oxidative stress, downregulation of LDHA and SOD2, and caspase-associated apoptosis. In contrast, PC-3 cells showed greater combinatorial susceptibility, a docetaxel dose-sparing effect, and a low glycolytic profile, with concomitant cytotoxicity and mitochondrial dysfunction. These findings identify DMF as a context-dependent metabolic modulator of docetaxel response, supporting further evaluation of DMF–DCT combinations as a potential therapeutic strategy in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelDimethyl FumarateProstatic NeoplasmsAntineoplastic AgentsHumansMaleCell Line, TumorApoptosisCell SurvivalOxidative StressMitochondriaGlucoseDrug SynergismSuperoxide Dismutase 2

Stichwörter der Autor:innen

combination therapydimethyl fumaratedocetaxelmetabolic reprogrammingrepurposing

Substanzen

DocetaxelDimethyl FumarateGlucoseAntineoplastic AgentsSuperoxide Dismutase 2

Autor:innen und Institutionen

  • Grupo de Investigación Biomédica y Biología Molecular, Facultad de Ciencias de la Salud, Universidad del Sinú, Montería 230001, Colombia.
  • Departamento de Ciencias Básicas, Escuela de Medicina, Universidad Industrial de Santander, Bucaramanga 680002, Colombia.
  • Grupo de Investigación en Farmacología y Metabolismo (FARMET), Universidad Industrial de Santander, Bucaramanga 680001, Colombia.
  • Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá 111321, Colombia.

ORCID-Profile: Andrés Coneo-Pretelt, Ana Peñata-Taborda, Lyda Espitia-Pérez, Mario Negrette-Guzmán, Nathalia Jones-Cifuentes, Bladimiro Rincón-Orozco, Pedro Espitia-Pérez

Förderung

  • Ministerio de Ciencia, Tecnología e Innovación
  • Ministry of Science, Technology, and Innovation of Colombia
  • Universidad del Sinú

Zitieren

APA

Coneo-Pretelt, A., Peñata-Taborda, A., Espitia-Pérez, L., Jiménez-Vidal, L., Negrette-Guzmán, M., Jones-Cifuentes, N., Rincón-Orozco, B., Aristizábal-Gutiérrez, F., & Espitia-Pérez, P. (2026). Metabolic Modulation by Dimethyl Fumarate Alters Docetaxel Responses in Prostate Cancer Cells. International Journal of Molecular Sciences, 27(14), 6209. https://doi.org/10.3390/ijms27146209

Vancouver

Coneo-Pretelt A, Peñata-Taborda A, Espitia-Pérez L, Jiménez-Vidal L, Negrette-Guzmán M, Jones-Cifuentes N, et al. Metabolic Modulation by Dimethyl Fumarate Alters Docetaxel Responses in Prostate Cancer Cells. International Journal of Molecular Sciences. 2026;27(14):6209. doi:10.3390/ijms27146209

BibTeX
@article{ConeoPretelt2026,
  author = {Coneo-Pretelt, Andrés and Peñata-Taborda, Ana and Espitia-Pérez, Lyda and Jiménez-Vidal, Luisa and Negrette-Guzmán, Mario and Jones-Cifuentes, Nathalia and Rincón-Orozco, Bladimiro and Aristizábal-Gutiérrez, Fabio and Espitia-Pérez, Pedro},
  title = {Metabolic Modulation by Dimethyl Fumarate Alters Docetaxel Responses in Prostate Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6209},
  doi = {10.3390/ijms27146209}
}
Kostenlos starten →